Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis - Wikidata - wikimedia - TriplyDB

Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis

Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis

http://www.wikidata.org/entity/Q34521577

about

Study of Leishmania pathogenesis in mice: experimental considerations Determinants for the development of visceral leishmaniasis disease Iron overload favors the elimination of Leishmania infantum from mouse tissues through interaction with reactive oxygen and nitrogen species B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis Comparative expression profiling of Leishmania: modulation in gene expression between species and in different host genetic backgrounds.Interleukin 32γ (IL-32γ) is highly expressed in cutaneous and mucosal lesions of American Tegumentary Leishmaniasis patients: association with tumor necrosis factor (TNF) and IL-10.Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia)Experimental transmission of Leishmania infantum by two major vectors: a comparison between a viscerotropic and a dermotropic strain.Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation.The immunotherapeutic role of regulatory T cells in Leishmania (Viannia) panamensis infection.Deception and manipulation: the arms of leishmania, a successful parasite Leukocytes infiltrate the skin and draining lymph nodes in response to the protozoan Leishmania infantum chagasi.Vectorborne Transmission of Leishmania infantum from Hounds, United States.Functional analysis of Leishmania cyclopropane fatty acid synthetase Balancing immunity and pathology in visceral leishmaniasis.Cross-species genetic exchange between visceral and cutaneous strains of Leishmania in the sand fly vector.Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model.Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.An intradermal environment promotes a protective type-1 response against lethal systemic monocytotropic ehrlichial infection Animal models for the analysis of immune responses to leishmaniasis.Xenodiagnosis of Leishmania donovani in BALB/c mice using Phlebotomus orientalis: a new laboratory model.Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease.Toll-Like Receptor 2 Targeted Rectification of Impaired CD8⁺ T Cell Functions in Experimental Leishmania donovani Infection Reinstates Host Protection The immunopathology of experimental visceral leishmaniasis.CD8(+) T cells in leishmania infections: friends or foes?Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani.Leishmania chagasi: homogenous metacyclic promastigotes isolated by buoyant density are highly virulent in a mouse model Comparative genomics: from genotype to disease phenotype in the leishmaniases.Experimental models in vaccine research: malaria and leishmaniasis.Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.DNA vaccines: a rational design against parasitic diseases.Natural killer cells in experimental and human leishmaniasis.Immune responses during cutaneous and visceral leishmaniasis.Polymerase chain reaction detection and inducible nitric-oxide synthase expression of Leishmania major in mice inoculated by two different routes.

P2860

Q26766230-BFDB884B-87EC-4790-83E4-9154C587E21A Q27027871-48DD4EC4-CB57-4603-8E0F-B54C9FAC42A5 Q27305261-9DDC46FA-DB62-4DF2-8388-079BA818B042 Q27317015-AEC78E9B-53FD-4CAF-9CD0-DF2DFCCDC019 Q27341915-A5C9E027-B016-4A58-9750-F961CACDCAF8 Q33479120-CAFEF970-CE67-4178-A9A0-0DBECD1E63A9 Q33633481-7F764F4D-CA44-485E-8192-3FD5733B1344 Q33783745-6D18F619-929B-40D8-B164-A94FBA1A2E89 Q33939303-7EC215D1-EBE1-4307-9EE3-0D6187DAB089 Q33939315-D575D45D-9C5F-4F9C-AD19-89F3246C8B15 Q34033343-88829831-D26A-4A96-BF5D-B99791C0260F Q34149280-EAA3CEFA-55CB-428B-8DB5-A501549BCFF4 Q34219774-70F78157-8FA1-423A-A384-988F2A6315F2 Q34369161-A7E0849D-4587-4464-9AF7-B494DA70DBC2 Q34484497-27144D8F-7916-4179-8B3B-BA3DEBE2E2B2 Q34502192-9FD3BDBC-50DE-4CDE-9F9B-C9D5D9306A21 Q34516403-355DD08B-C745-4280-8B61-C2C2EA365DE9 Q34587432-369CE4D0-AD71-4919-83D6-71A4947172A4 Q34601558-C7378BBA-CB74-4DDA-B123-EC3A1454F9CD Q34639315-4FB4EBE9-F986-4620-986E-43097F83A1EB Q34662190-72EF24D9-2601-47D4-87D3-51B10825BB7F Q34975715-6FF1A2FC-1210-43BA-A19C-0772A82AAE1B Q35188674-3430EB96-622A-4B0E-80BC-5819BFD8B6B9 Q35190896-47FE3E37-7C5B-491B-BECF-9F95B4FBAB98 Q35530589-9C68E081-1FB4-41F1-84AD-BEC2C633791D Q35786380-2552DEC0-DB47-4189-A931-14123E1F1DAA Q35838927-B6FD59CD-3AA4-42E0-B518-C69AE35E75B2 Q35884243-ECAEB249-4432-47D0-B0E6-D325AD2AB3B3 Q35927465-81CFACA1-317D-43AB-8634-2664F4DA4A14 Q36251325-B4AAEA6F-7A59-487F-BF4D-471E302CDB3D Q36331305-B40974D4-0861-4EE3-8BE5-F844598A967B Q36421468-7452F623-7029-4E82-BDDA-601A89643F7F Q36508286-060B3C4E-65CC-46EA-8F15-CC9B96C6148A Q36889371-D713F086-7FD2-4A5D-BA9B-D0AF1995579C Q37371348-69C8562C-5D05-415A-B696-906677E25636 Q37434214-9C09F20A-25A5-43B8-9DFB-22ECA0BC0514 Q37682900-08EC88A7-CF32-42F0-9A80-CAA6BDCD5E6E Q38037557-49890A6C-52FA-4C8A-AA86-D7456465E898 Q38235268-76A1E3AF-3212-4AF9-B7B9-D6E0B655D855 Q38776366-59ACE903-D75A-4F97-A2D9-634BC9ACBAEC

P2860

Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis

http://www.wikidata.org/entity/Q34521577

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Intradermal infection model fo ...... murine visceral leishmaniasis

@ast

Intradermal infection model fo ...... murine visceral leishmaniasis

@en

Intradermal infection model fo ...... murine visceral leishmaniasis

@nl

type

label

Intradermal infection model fo ...... murine visceral leishmaniasis

@ast

Intradermal infection model fo ...... murine visceral leishmaniasis

@en

Intradermal infection model fo ...... murine visceral leishmaniasis

@nl

prefLabel

Intradermal infection model fo ...... murine visceral leishmaniasis

@ast

Intradermal infection model fo ...... murine visceral leishmaniasis

@en

Intradermal infection model fo ...... murine visceral leishmaniasis

@nl

P1433

Q34521577-D72E2988-7A00-40EE-BD8C-E71CBE60C969

P1476

Q34521577-3666A5AF-1A93-4F9A-B10B-29A1F8848F68

P2093

Q34521577-2ED0C453-94C7-4FF0-B656-A1A81E30419C

Q34521577-3EAE7171-2053-42D9-9DA8-64E92CC5C58A

Q34521577-925E59C9-6A26-4796-906B-7758E0B66381

Q34521577-9BA14160-5230-425D-BF26-750028B372BE

Q34521577-D814B593-2542-4681-AE0E-1B4A69046493

P2860

Q34521577-023EF4FA-1D3F-4ABC-B871-F49834EAAF64

Q34521577-03DB538A-F077-482E-B3CE-C3E3C11F5265

Q34521577-09DEC767-4E23-45FE-9955-32D619617CA5

Q34521577-0C6AD46B-2E6D-4959-B45D-AA923F174F99

Q34521577-0DCA892B-B910-4486-940B-78C77096869A

Q34521577-0DD34478-C438-431A-9C59-DD05F756FE3B

Q34521577-12A7E304-1B02-420E-AADA-D9FE31200BB1

Q34521577-171E4600-831F-4FF6-95C8-FFF8BB0657C4

Q34521577-1AC71569-F87B-4C32-982B-FBC8D993156A

Q34521577-2CF101CE-C3F8-4C2F-ABB1-6C00201BB89A

P304

Q34521577-4B3D9CD8-3AF5-4043-A6A7-BDA04851B810

P31

Q34521577-6D8DF1AA-19B0-4C30-9DFF-66B585329ECD

P356

Q34521577-C0719F7A-B145-4488-A25A-EBB65FCE7AF4

P407

Q34521577-3BF82C65-1820-4FE9-815D-93A91BCF2240

P433

Q34521577-3F0F4F34-9828-4425-98C5-FC5660C21B8D

P478

Q34521577-7BC29797-501E-4321-BA8B-8A52E3A45783

P50

Q34521577-D3025551-CE18-4EE1-A3C3-5907FFB37207

Q34521577-FC6DC208-0584-4312-B391-54B56A95CD60

P577

Q34521577-D94C50C3-E727-420A-A793-C416D790E2E2

P5875

Q34521577-B332728E-C51F-4BA2-A039-E284F3782694

P698

Q34521577-A1C3DB3E-51CA-42A9-826A-44F407FD84AD

P921

Q34521577-E89979C5-0A3E-4159-8030-8D4B81FDCC88

Q34521577-FA33E3B8-1180-434A-8999-1B4DD8465F54

P932

Q34521577-ED5CE9EE-38DE-46FC-A2EB-8A24AF4FDAD5

P356

IAI.71.1.401-410.2003

P1433

Infection and Immunity

P1476

Intradermal infection model fo ...... murine visceral leishmaniasis

@en

P2093

Diane McMahon-Pratt

http://www.w3.org/2001/XMLSchema#string

K Goldsmith-Pestana

http://www.w3.org/2001/XMLSchema#string

L Munstermann

http://www.w3.org/2001/XMLSchema#string

L Soong

http://www.w3.org/2001/XMLSchema#string

Saeed Ahmed

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma

Interleukin 10 production correlates with pathology in human Leishmania donovani infections

Dendritic cells and the control of immunity

Epidemiology of the leishmaniases.

Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library.

Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms.

Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.

Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events.

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

P304

401-410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.71.1.401-410.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

María Colmenares

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6145938

http://www.w3.org/2001/XMLSchema#string

P698

12496190

http://www.w3.org/2001/XMLSchema#string

P921

visceral leishmaniasis

P932

143149

http://www.w3.org/2001/XMLSchema#string